Hyoscine Butylbromide (Buscopan)

DRUG NAME: Hyoscine Butylbromide (Scopolamine Butylbromide)

---

Therapeutic Class: Antispasmodic

---

Subclass

Quaternary Ammonium Antimuscarinic (Peripherally-Acting)

---

Schedule (India):

---

Route(s):

• Oral (tablets — swallowed whole)
• IV (intravenous — bolus injection)
• IM (intramuscular)
• Rectal (suppository — very limited availability in India)

---

Biosimilar Status:

---

Formulations Available in India:

---

PHARMACOKINETICS

---

---

• Local vs systemic action — the critical distinction for oral dosing: When hyoscine butylbromide is taken orally, <1% is absorbed. The clinical antispasmodic effect in the GI tract is due to the drug acting on muscarinic receptors in the gut wall from the luminal side, as the drug passes through the GI tract. This is fundamentally different from most other drugs, where oral dosing implies systemic absorption → systemic distribution → target organ effect. For hyoscine butylbromide, the oral tablet essentially acts as a ”topical“ drug for the GI tract.
• Implication for non-GI indications (oral route): Because oral hyoscine butylbromide has negligible systemic absorption, oral tablets will NOT be effective for conditions requiring systemic antimuscarinic action (e.g., urinary tract spasm, biliary spasm where the spasm is at the sphincter of Oddi — which requires systemic drug levels). For these indications, the parenteral route (IV/IM) must be used to achieve adequate systemic drug levels. This is a common prescribing error in Indian practice.
• Non-linear PK: No clinically significant non-linear pharmacokinetics have been reported at therapeutic doses.
• Placental transfer: Data limited. The quaternary ammonium structure suggests limited placental transfer, but some degree of transfer cannot be excluded. See Pregnancy section.
• Breast milk excretion: Data limited. Given the quaternary ammonium structure, transfer into breast milk is expected to be minimal.

---

---

ADULT INDICATIONS + DOSING FOR CLINICIAN USE ONLY

---

Primary Indications (Approved / Standard in India)

---

• Mild-to-moderate GI cramps (outpatient/OPD): Oral tablets — effective, safe, and affordable.
• Severe acute GI colic (emergency department): IV bolus — fastest onset; provides diagnostic value (if spasm resolves with antispasmodic, less likely to be a surgical abdomen).
• Vomiting patient who cannot take oral medication and IV access unavailable: IM injection or rectal suppository (if available).

1. When to prefer this drug over alternatives:
   • Prefer over dicyclomine when a drug with no CNS effects is needed (dicyclomine crosses the BBB and causes drowsiness; hyoscine butylbromide does not). This is especially important for patients who drive, operate machinery, or need to remain alert.
   • Prefer over atropine for GI spasm because atropine has significant systemic anticholinergic effects (tachycardia, mydriasis, urinary retention, CNS effects) at antispasmodic doses.
   • Prefer over drotaverine or mebeverine when an antimuscarinic mechanism is specifically needed (e.g., confirmed muscarinic-mediated spasm, or when direct smooth muscle relaxants have been ineffective).
   • ℹ️ Drotaverine (Drotin) is more commonly used in Indian emergency departments for acute colic than hyoscine butylbromide, primarily due to familiarity and availability. Both are acceptable choices; hyoscine butylbromide has a longer history of use and a different mechanism (antimuscarinic vs PDE-4 inhibition).
2. When NOT to use even though technically indicated:
   • ⚠️ Mechanical bowel obstruction or suspected surgical abdomen — antispasmodics may mask symptoms and delay surgical intervention. Always rule out surgical causes of acute abdominal pain before administering antispasmodics.
   • Paralytic ileus — anticholinergic drugs worsen GI stasis.
   • Toxic megacolon — risk of worsening dilation and perforation.
   • Patients with myasthenia gravis (antagonises cholinesterase inhibitors).
   • Patients with untreated narrow-angle glaucoma (parenteral route — systemic anticholinergic effect; oral route risk is minimal due to negligible absorption).
3. NLEM India status: Hyoscine butylbromide is NOT listed in NLEM India 2022. Dicyclomine is listed as an antispasmodic in the NLEM. Drotaverine is also not listed.
4. Typical time to expected clinical response:
   • Oral: 15–30 minutes for onset; full effect within 30–60 minutes.
   • IV: 1–5 minutes.
   • IM: 15–30 minutes.
   • If no response within 30 minutes (oral) or 15 minutes (IV), consider alternative diagnosis (e.g., surgical abdomen) or alternative drug.
5. Criteria for treatment failure and switching:
   • If 3–5 days of oral hyoscine butylbromide at maximum doses fails to relieve recurrent GI spasm, consider:
     • Re-evaluation of diagnosis (is the pain truly spasmodic?).
     • Trial of mebeverine (135 mg TDS — direct smooth muscle relaxant, better tolerated long-term for IBS) or drotaverine (80 mg TDS).
     • Trial of peppermint oil capsules (enteric-coated — evidence for IBS-related spasm).
     • Gastroenterology referral if symptoms are persistent, progressive, or associated with red flags (weight loss, bleeding, anaemia, age >45 with new symptoms).
   • For acute colic unresponsive to IV hyoscine butylbromide, switch to IV drotaverine 40–80 mg or consider opioid analgesia (tramadol/morphine) with appropriate monitoring.
6. Mandatory baseline investigations:
   • No mandatory laboratory investigations before starting oral hyoscine butylbromide for self-limiting GI cramps.
   • RECOMMENDED before IV use in acute abdomen: Basic blood panel (CBC, electrolytes, serum amylase/lipase if pancreatitis suspected), abdominal X-ray (to rule out perforation/obstruction), and clinical assessment for peritonitis.
   • MANDATORY: Clinical assessment to exclude surgical abdomen before attributing pain to spasm.
7. Specialist initiation:Not required for oral use. Any registered medical practitioner can prescribe. IV use is typically in the emergency department or inpatient setting supervised by an attending physician.
8. Indian guideline source: API Textbook of Medicine (current edition) mentions antispasmodics for functional GI disorders and IBS; hyoscine butylbromide is listed as an option. Indian Society of Gastroenterology (ISG) IBS Consensus Statement (2018) includes antispasmodics as a treatment option for abdominal cramps in IBS, without specifying a single preferred agent. No specific ICMR guideline addresses antispasmodic choice.
9. Key disease-specific safety warning: ⚠️ IBS-specific: Hyoscine butylbromide provides symptom relief only — it does not modify the underlying disease process in IBS. It is most effective for the cramping/pain component of IBS; it does not treat diarrhoea, constipation, or bloating. It may worsen constipation-predominant IBS (IBS-C) through its antimotility effect. Prefer mebeverine for IBS-C patients. Hyoscine butylbromide is better suited for IBS-D (diarrhoea-predominant) or IBS-M (mixed) where both spasm relief and mild reduction in GI motility are desirable.
10. Common dose adjustment scenarios:
    • Elderly: No formal dose adjustment for oral use (negligible systemic absorption). For parenteral use, use standard dose with monitoring for tachycardia and urinary retention. See ELDERLY section.
    • Renal impairment: No adjustment for oral use. Use parenteral route with caution in severe renal impairment — monitor for prolonged anticholinergic effects.
    • Hepatic impairment: No adjustment for oral use. Parenteral use — use with caution in severe hepatic impairment.
    • Concurrent anticholinergic drugs: Reduce dose or avoid if patient is already on multiple anticholinergics.

---

1. When to prefer over alternatives: Consider as an adjunct to NSAIDs in acute renal colic. Prefer over drotaverine if the clinician desires a specifically antimuscarinic mechanism. However, drotaverine (40–80 mg IV) is more commonly used in Indian emergency departments for renal colic and has some evidence for superior efficacy. The choice is often based on institutional protocol and clinician preference.
2. When NOT to use:
   • Do NOT use oral tablets expecting systemic antispasmodic effect on ureters — prescribe parenteral formulation.
   • Do NOT use as a substitute for adequate analgesia — antispasmodic alone is insufficient for moderate-to-severe colic.
   • Suspected obstructive uropathy with anuria — urgent urology/nephrology referral, not antispasmodic therapy.
   • Concurrent sepsis with renal calculus (pyonephrosis) — requires urgent drainage, not antispasmodic.
3. NLEM India status: Not listed. Diclofenac injection is listed in NLEM for acute pain management.
4. Time to response: IV: 1–5 minutes. If no response within 15 minutes after IV dose, consider repeating once. If still unresponsive, escalate analgesic therapy (opioids — tramadol 50–100 mg IV, or morphine 2–5 mg IV in titrated doses).
5. Treatment failure criteria: If colic persists despite 2 doses of IV hyoscine butylbromide + adequate analgesia, consider: obstructing stone requiring intervention, alternative diagnosis (AAA, mesenteric ischaemia, ovarian torsion), or urology referral for DJ stent/percutaneous nephrostomy.
6. Mandatory baseline investigations:
   • MANDATORY: Urine analysis (haematuria supports stone diagnosis), serum creatinine (rule out AKI from obstruction), ultrasound KUB (detect hydronephrosis).
   • RECOMMENDED: Non-contrast CT KUB (gold standard for stone detection — availability varies in Indian centres). CBC (rule out infection). Serum electrolytes.
7. Specialist initiation: Not required for initial emergency management. Urology referral for stones >5–6 mm, obstructive features, recurrent colic, or suspected complicated stone disease.
8. Indian guideline source: Urological Society of India (USI) guidelines on urolithiasis management recommend NSAIDs as first-line analgesia with antispasmodics as adjunctive therapy. API Textbook of Medicine references antispasmodics for colic management.
9. Key safety warning: ⚠️ Do NOT delay imaging and definitive management by repeated antispasmodic dosing. Renal colic with associated sepsis (fever, rigors, pyuria) or anuria requires EMERGENCY urological intervention, not continued antispasmodic therapy.
10. Dose adjustment: No adjustment for the typical 1–2 parenteral doses used in acute colic. Avoid repeated dosing in patients with severe renal impairment.

---

1. Prefer over alternatives: Hyoscine butylbromide is one of the most commonly used antispasmodics for biliary colic in Indian emergency departments. Alternative: drotaverine 40–80 mg IV. Both are acceptable; choice is institution-dependent. ℹ️ Morphine was historically avoided in biliary colic due to theoretical sphincter of Oddi spasm, but current evidence suggests this concern is overstated. If pain is severe, opioids (with or without antispasmodic) should NOT be withheld based on this outdated concern.
2. When NOT to use: Suspected cholangitis (Charcot’s triad — pain, fever, jaundice) — requires urgent biliary drainage. Suspected gallbladder perforation or biliary peritonitis — surgical emergency. Do NOT delay cholecystectomy referral by relying on chronic antispasmodic therapy for recurrent biliary colic.
3. NLEM status: Not listed.
4. Time to response: IV: 1–5 minutes.
5. Treatment failure: Persistent colic despite antispasmodic + analgesic → reassess diagnosis (acute cholecystitis? choledocholithiasis? pancreatitis?); surgical/gastroenterology referral.
6. Baseline investigations: MANDATORY: LFT, serum amylase/lipase (rule out pancreatitis), USG abdomen. RECOMMENDED: CBC (leucocytosis if cholecystitis).
7. Specialist initiation: Not required for acute management. Surgical referral for definitive management (cholecystectomy).
8. Indian source: API Textbook of Medicine; standard surgical textbooks used in Indian practice (SRB’s Manual of Surgery, Bailey & Love).
9. Safety warning: ⚠️ Anticholinergic drugs may theoretically delay gallbladder emptying with chronic use. Do NOT use chronic oral hyoscine butylbromide as a substitute for cholecystectomy in symptomatic gallstone disease.
10. Dose adjustment: Standard dosing for acute episode. No special adjustment.

---

1. When to prefer over alternatives: Consider when NSAIDs alone are insufficient for dysmenorrhoea, or when NSAIDs are contraindicated/not tolerated (e.g., peptic ulcer disease, NSAID allergy, aspirin-exacerbated respiratory disease). The FDC with paracetamol (Buscopan Plus) provides dual analgesic + antispasmodic action and is a reasonable first-choice for mild-to-moderate primary dysmenorrhoea. NSAIDs (mefenamic acid 500 mg TDS, ibuprofen 400 mg TDS) remain the first-line treatment for moderate-to-severe primary dysmenorrhoea supported by stronger evidence.
2. When NOT to use: Secondary dysmenorrhoea (endometriosis, adenomyosis, fibroids) requires definitive gynaecological management — antispasmodics provide symptomatic relief only and should NOT delay workup. Red flags: progressively worsening dysmenorrhoea, heavy menstrual bleeding, intermenstrual bleeding, infertility — warrant gynaecological referral.
3. NLEM status: Not listed. Mefenamic acid and ibuprofen are available in NLEM as analgesics.
4. Time to response: Oral: 15–30 minutes.
5. Treatment failure: If cramps persist despite 3 days of maximal-dose hyoscine butylbromide + NSAID, reassess for secondary causes. Consider hormonal therapy (combined OCP, IUS) for recurrent severe primary dysmenorrhoea — gynaecology referral.
6. Baseline investigations: None mandatory for primary dysmenorrhoea in young women with typical history. If secondary causes suspected: pelvic ultrasound.
7. Specialist initiation: Not required. Primary care appropriate.
8. Indian source: FOGSI (Federation of Obstetric and Gynaecological Societies of India) practice guidance on dysmenorrhoea management.
9. Safety warning: No specific disease-related safety warning unique to dysmenorrhoea beyond standard anticholinergic cautions.
10. Dose adjustment: Standard dosing. Self-limiting course (2–3 days/month).

---

1. When to prefer: Standard agent for GI endoscopy antispasmodic support in India. Preferred over glucagon due to cost and availability. Preferred over hyoscine hydrobromide because CNS effects (sedation, amnesia) from hyoscine hydrobromide are undesirable during endoscopy where the patient’s cooperation is needed (especially in unsedated or lightly sedated endoscopy, which is still common in many Indian centres).
2. When NOT to use: Patients with unstable cardiac rhythm — tachycardia from anticholinergic effect may be hazardous. Not all endoscopic procedures require antispasmodic — routine diagnostic EGD in a cooperative patient often does not need it. Used selectively when spasm impairs visualisation or when ERCP requires sphincter relaxation.
3. NLEM status: Not listed.
4. Time to response: 1–5 minutes IV.
5. Treatment failure: If spasm persists despite 40 mg IV, consider glucagon 0.5–1 mg IV (if available). Alternatively, accept suboptimal visualisation and repeat procedure if needed.
6. Baseline investigations: Standard pre-endoscopy assessment (coagulation profile, consent). No specific investigation for the antispasmodic component.
7. Specialist initiation: Used by gastroenterologists, endoscopists, and radiologists during procedures. Not a primary care prescription.
8. Indian source: Indian Society of Gastroenterology (ISG) endoscopy practice — standard institutional protocols. ESGE (European Society of Gastrointestinal Endoscopy) guidelines referenced for procedural standards adapted to Indian practice.
9. Safety warning: ⚠️ Tachycardia: Monitor heart rate. In patients with pre-existing tachycardia or ischaemic heart disease, the additional heart rate increase from IV hyoscine butylbromide may be poorly tolerated. Use with caution in such patients — consider proceeding without antispasmodic or using glucagon (which does not cause tachycardia). ⚠️ Urinary retention post-procedure: Particularly in elderly males with BPH. Ensure the patient has voided before discharge from the endoscopy unit.
10. Dose adjustment: No dose adjustment needed for this single-dose procedural use. Use standard 20 mg IV.

---

Secondary Indications — Adults Only (Off-label)

---

• Multiple small Indian RCTs (primarily from medical college hospitals) have evaluated hyoscine butylbromide for cervical dilation. Results are heterogeneous: some studies report a statistically significant reduction in the duration of the active phase of the first stage of labour (by 1–3 hours), while others show no significant benefit.
• A Cochrane review on antispasmodics in labour (including hyoscine butylbromide, drotaverine, and valethamate) found low-to-moderate quality evidence suggesting some reduction in labour duration, but the clinical significance was uncertain, and the risk of bias in included studies was substantial.
• Drotaverine (Drotin) has better quality evidence for cervical dilation acceleration than hyoscine butylbromide in the Indian literature and is recommended by some FOGSI practice guidelines over hyoscine butylbromide for this purpose.
• Level of evidence: Moderate (multiple RCTs exist, but methodological quality is variable; no large, high-quality multicentre trial definitively establishes benefit).

• ⚠️ FOGSI has not issued a formal consensus guideline endorsing routine use of hyoscine butylbromide for labour augmentation. Some FOGSI publications reference it as an option; others recommend drotaverine as the preferred antispasmodic.
• ⚠️ Monitor FHR closely — transient fetal tachycardia has been reported (though less frequently than with hyoscine hydrobromide, because hyoscine butylbromide has minimal placental transfer as a quaternary ammonium compound).
• ⚠️ Maternal tachycardia — monitor. Usually transient and mild.
• ⚠️ Dry mouth — common; provide oral fluids.
• Do NOT use in prelabour / latent phase — no evidence of benefit and may delay recognition of prolonged latent phase.
• Do NOT substitute for oxytocin augmentation in cases of inadequate uterine contractions — these are different mechanisms.
• Use only in uncomplicated term pregnancies. Contraindicated if caesarean section is planned or if cervical dilation is progressing normally without intervention.

---

---

---

---

---

---

PAEDIATRIC DOSING (Specialist Only)

---

• ⚠️ Age restriction: Hyoscine butylbromide tablets are NOT recommended in children below 6 years of age per most CDSCO product inserts (including Buscopan, Sanofi). The injectable formulation is generally not recommended in infants below 1 year unless under specialist supervision in a hospital setting.
• Safety monitoring requirements specific to paediatric use:
  • Monitor heart rate (tachycardia — children may be more sensitive to the chronotropic effect of anticholinergics via systemic absorption from parenteral route)
  • Monitor temperature (anticholinergic suppression of sweating — relevant in Indian hot climate, particularly in febrile children)
  • Monitor hydration status (dry mouth + reduced fluid intake in unwell children → dehydration risk)
  • Monitor for urinary retention (especially postoperative paediatric patients)
  • Monitor bowel sounds and abdominal distension (especially in neonates and infants — risk of ileus)
• Formulation suitability for children:
  • Oral tablet (10 mg): Suitable for children ≥6 years who can swallow tablets whole. Film-coated — should NOT be crushed (bitter taste, no stability data for crushed form). No paediatric oral liquid formulation (syrup/suspension) of hyoscine butylbromide is commercially available in India. This is a significant practical limitation for young children.
  • Injectable (20 mg/mL): Can be used in children ≥1 year (some references permit use from 1 month under specialist supervision). Allows accurate weight-based dosing. Requires dilution for small-volume paediatric doses.
  • Suppository (10 mg): Very limited availability in India. Not practical for routine paediatric use.
• Palatability: Not applicable — no oral liquid formulation exists. Tablets are film-coated and should not be chewed (bitter taste if coating is disrupted).
• Age-specific pharmacokinetic differences:
  • Oral bioavailability remains negligibly low (<1%) in children, as in adults — the drug acts locally in the GI lumen.
  • After parenteral administration, neonates and infants may have prolonged drug effects due to immature hepatic hydrolysis pathways and reduced renal clearance. Use with extra caution in this age group.
  • The quaternary ammonium structure ensures NO CNS effects even in children — this is an advantage over dicyclomine (which crosses the BBB and has caused serious CNS adverse events including seizures and apnoea in infants).

---

---

---

1. When to prefer over alternatives: Consider when a non-sedating antispasmodic is needed in children. The absence of CNS effects is a significant advantage over dicyclomine in children. Mebeverine (available as tablets 135 mg — not easily dose-adjustable for children; suspension not widely available in India) is an alternative for older children (≥12 years typically). Drotaverine is used in some Indian paediatric emergency departments but has limited paediatric-specific data.
2. When NOT to use:
   • ⚠️ Children <6 years (oral tablets) — no appropriate formulation.
   • ⚠️ Recurrent abdominal pain in children without adequate evaluation — first rule out organic causes (appendicitis, intussusception, mesenteric lymphadenitis, worm infestation, UTI, constipation, celiac disease) before attributing pain to ”functional spasm.“
   • ⚠️ Intussusception: Anticholinergics may mask the colicky pain of intussusception and delay diagnosis of this surgical emergency. Maintain a high index of suspicion in children 6 months to 3 years with episodic severe abdominal pain.
3. NLEM status: Not listed. No paediatric antispasmodic is specifically listed in the NLEM paediatric section.
4. Time to response: Oral: 15–30 minutes. IV: 1–5 minutes.
5. Treatment failure: If abdominal pain is recurrent despite antispasmodic therapy, reassess diagnosis. Consider functional abdominal pain disorder management (biopsychosocial approach — dietary modification, stress management, cognitive behavioural therapy, probiotics). Paediatric gastroenterology referral for alarm features (weight loss, bloody stools, nocturnal symptoms, persistent vomiting, family history of IBD).
6. Baseline investigations: None mandatory for a single episode of typical spasmodic abdominal pain. For recurrent pain: stool examination for ova/parasites (high prevalence of intestinal parasitosis in Indian children), urine routine (rule out UTI), CBC, and abdominal ultrasound. IAP recommends a step-wise diagnostic approach for recurrent abdominal pain.
7. Specialist initiation: Oral tablets for self-limiting abdominal cramps can be prescribed by a paediatrician in OPD. IV use should be supervised by a paediatrician or emergency physician.
8. Indian source: IAP Textbook of Pediatrics (current edition) — section on functional abdominal pain and recurrent abdominal pain in children. IAP Guidelines on Functional Gastrointestinal Disorders in Children.
9. Safety warning: ⚠️ Monitor temperature in febrile children receiving hyoscine butylbromide (parenteral) — anticholinergic suppression of sweating can impair thermoregulation, especially in the Indian hot climate.
10. Dose adjustment: Reduce IV dose to 0.3 mg/kg in children with hepatic impairment. No adjustment for oral use (negligible absorption).

---

---

Secondary Indications — Paediatric (Off-label)

---

---

MISSED DOSE / DELAYED DOSE GUIDANCE

---

---

---

---

---

• No risk of rebound — stopping the drug simply allows return of spasm symptoms.
• No withdrawal syndrome — can be stopped abruptly at any time.
• No re-titration needed — the drug can be resumed at the previous dose after any duration of non-adherence.
• Not a biologic — no immunogenicity concern.
• Not a narrow therapeutic index drug — no risk of toxicity on resumption at the prior dose.

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

---

---

Example: A 15 kg child presents with acute abdominal colic requiring IV hyoscine butylbromide at 0.5 mg/kg.

• • Required dose = 15 × 0.5 = 7.5 mg
  • Using the standard 20 mg/mL ampoule:
    • Volume to draw from undiluted ampoule = 7.5 / 20 = 0.375 mL — difficult to measure accurately with a standard syringe.
  • Better approach: Dilute to 2 mg/mL (as described above: 1 mL [20 mg] + 9 mL NaCl = 10 mL of 2 mg/mL solution)
    • Volume to draw from diluted solution = 7.5 / 2 = 3.75 mL — much easier to measure accurately.
  • Administer as a slow IV bolus over 1–2 minutes.
  • Monitor heart rate during and for 15 minutes after administration.

---

---

---

---

---

---

---

---

RENAL ADJUSTMENT

---

---

---

HEPATIC ADJUSTMENT

---

• ⚠️ Anticholinergic effects on GI motility in patients with hepatic encephalopathy: In patients with cirrhosis and hepatic encephalopathy, reduced GI motility from anticholinergic drugs can worsen constipation, reduce lactulose efficacy (which depends on osmotic effect and gut transit), and thereby worsen ammonia clearance, potentially precipitating or worsening hepatic encephalopathy. Avoid chronic or repeated anticholinergic use in patients with cirrhosis and hepatic encephalopathy. A single dose for acute colic is acceptable.

---

• Oral route: No dose adjustment needed in ANY degree of renal or hepatic impairment, because the drug acts locally in the GI lumen and <1% is absorbed systemically.
• Parenteral route: Use with increasing caution as organ impairment worsens — primarily because the fully absorbed drug depends on hepatic hydrolysis and renal excretion for clearance. Single doses for acute colic are safe across all impairment levels; repeated or scheduled dosing requires monitoring and dose-interval extension in moderate-to-severe impairment.

---

CONTRAINDICATIONS

---

---

CAUTIONS

---

---

---

PREGNANCY

---

---

---

---

LACTATION

---

---

---

---

ELDERLY

---

---

• Delirium / acute confusion
• Cognitive impairment
• Sedation / drowsiness
• Hallucinations
• Falls from CNS depression

---

---

• ACB Score: 1 (possible anticholinergic activity) — this is the lowest score for an antimuscarinic drug.
• The low ACB score reflects the fact that the drug does NOT cross the blood-brain barrier and therefore does NOT exert central anticholinergic effects (which are the primary driver of cognitive impairment in elderly patients).
• For comparison:
  • Hyoscine hydrobromide: ACB 3 (definite, high cognitive effect)
  • Dicyclomine: ACB 3
  • Atropine: ACB 3
  • Oxybutynin: ACB 3
  • Amitriptyline: ACB 3
  • Chlorpheniramine: ACB 3
  • Hyoscine butylbromide: ACB 1

---

---

---

---

MAJOR DRUG INTERACTIONS

---

---

---

MODERATE DRUG INTERACTIONS

---

---

---

COMMON ADVERSE EFFECTS

---

---

---

---

---

SERIOUS ADVERSE EFFECTS

---

---

---

---

MONITORING REQUIREMENTS

---

---

---

---

---

• Single-dose parenteral use: Monitoring can be discontinued once the patient is haemodynamically stable, has voided, and has no signs of anticholinergic adverse effects — typically 2–4 hours after the dose.
• Regular oral use: No ongoing monitoring is required beyond periodic clinical review of symptom control and bowel habit.

---

PATIENT COUNSELLING

---

---

• Tablets: ”Swallow the tablet whole with a glass of water. Do not chew or crush it — it has a special coating to prevent bitter taste. You can take it with or without food, but taking it 30 minutes before meals may work better if your cramps are related to eating.“
• Injection: ”This will be given to you by a doctor or nurse in the hospital. You do not need to do anything.“
• Suppository (if prescribed — rare): ”Remove the foil wrapper completely. Insert the pointed end gently into the back passage (rectum). Try to keep it inside for at least 30 minutes.“

---

---

• Dry mouth — sip water frequently; this usually goes away on its own.
• Mild constipation — eat fibre-rich foods (fruit, vegetables, whole grains) and drink plenty of water.
  If you receive this medicine as an injection, you may feel your heart beating a little faster for a few minutes — this is temporary and usually not a problem."

---

• Inability to pass urine for more than 6–8 hours (especially if you have prostate problems)
• Severe stomach pain that gets worse despite taking the medicine (this could mean a different problem that needs urgent attention)
• Very fast heartbeat that does not settle, or chest pain
• High fever with very dry, hot skin and no sweating (especially in summer)
• Severe skin rash, swelling of face/lips/tongue, or difficulty breathing (this could be an allergic reaction — very rare)
• Severe constipation with bloating and no passage of gas"

---

• ”There are no special food restrictions with this medicine.“
• ”Alcohol: This medicine does NOT interact with alcohol the way some other medicines do. However, alcohol may worsen your stomach symptoms, so moderate your intake.“
• ”⚠️ Hot weather (Indian summer): If you receive the injection form, avoid excessive heat exposure for a few hours after — the medicine can temporarily reduce your ability to sweat, which could make you overheat. Drink plenty of water and stay in a cool place.“
• ”Driving: You CAN drive while taking the tablets — this medicine does NOT cause drowsiness. However, if you feel dizzy after receiving the injection, wait until you feel normal before driving.“

---

---

---

---

---

• Elderly: Watch for inability to pass urine (especially elderly men with prostate problems), worsening constipation, or fast heartbeat after receiving the injection. Ensure adequate water intake. Keep the patient cool, especially in summer.
• Children (≥6 years on tablets): The tablet must be swallowed whole — do not crush it. Make sure the child drinks enough water. Watch for stomach bloating, constipation, or reduced urination. Keep medicines out of children’s reach — the sugar-coated tablet may look appealing to younger siblings."

---

---

BRANDS AVAILABLE IN INDIA

---

---

---

---

---

PRICE RANGE (INR)

---

---

---

• Drotaverine 80 mg tablet (Drotin, Lupin): ₹3–5 per tablet — comparable cost.
• Mebeverine 135 mg tablet (Colospa, Abbott): ₹5–8 per tablet — slightly more expensive.
• Dicyclomine 20 mg tablet (Cyclopam, Indoco): ₹1–2 per tablet — cheapest antispasmodic, but causes drowsiness.

---

CLINICAL PEARLS

---

---

VERSION

---

REFERENCES

---

1. CDSCO Product Insert — Buscopan (hyoscine butylbromide) tablets 10 mg and injection 20 mg/mL, Sanofi India Limited. Approved indications, contraindications, dosing, pharmacokinetics, and adverse effects for the Indian market. Most recently reviewed insert version (2023–2024).
2. CDSCO Product Insert — Buscopan Plus (hyoscine butylbromide 10 mg + paracetamol 500 mg), Sanofi India Limited. FDC-specific indications and dosing. Most recently reviewed insert version (2023–2024).
3. Indian Pharmacopoeia 2022 (IP 2022), Indian Pharmacopoeia Commission, Ghaziabad. 8th Edition. Monograph on Hyoscine Butylbromide Tablets and Injection — specifications and official standards.
4. National List of Essential Medicines (NLEM) India 2022, Ministry of Health & Family Welfare, Government of India. Hyoscine butylbromide is NOT listed. Dicyclomine is listed as an antispasmodic. Drotaverine is not listed.
5. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Chapter 9: Muscarinic Receptor Agonists and Antagonists. Pharmacology of quaternary ammonium antimuscarinics — mechanism of action, distinction between tertiary and quaternary amines, pharmacokinetics (negligible oral bioavailability of quaternary ammonium compounds), peripheral vs central effects. Used for pharmacological depth; deferred to CDSCO product inserts for Indian-specific labelling.
6. Harrison’s Principles of Internal Medicine, 21st Edition (2022). Sections on irritable bowel syndrome, biliary colic, renal colic, and functional GI disorders — treatment references.
7. API Textbook of Medicine, 11th Edition (2019), Association of Physicians of India. Sections on IBS management, functional GI disorders, and abdominal colic. References antispasmodics as a treatment option for IBS without specifying a single preferred agent.
8. Indian Society of Gastroenterology (ISG) Consensus Statement on Irritable Bowel Syndrome (2018). Recommends antispasmodics for IBS-related abdominal cramps; lists hyoscine butylbromide, mebeverine, dicyclomine, and drotaverine as options.
9. Indian Association of Palliative Care (IAPC) Treatment Guidelines. Symptom management in terminal illness: management of death rattle (terminal respiratory secretions). Lists hyoscine butylbromide, hyoscine hydrobromide, and glycopyrrolate as antisecretory agents with guidance on agent selection.
10. Cochrane Database of Systematic Reviews — Antispasmodics in Labour. Samuels LA et al., Cochrane reviews on hyoscine butylbromide and drotaverine for cervical dilation. Referenced for Secondary Indication 1 (labour acceleration) and Clinical Pearl 3. Low-to-moderate quality evidence for modest benefit.
11. FOGSI (Federation of Obstetric and Gynaecological Societies of India) — Practice references and publications on labour management. No formal consensus guideline endorsing routine hyoscine butylbromide for cervical dilation was identified. Some FOGSI publications reference antispasmodics as an option, with drotaverine favoured in some publications.
12. IAP Textbook of Pediatrics, 6th Edition (2021), Indian Academy of Pediatrics. Sections on recurrent abdominal pain in children, functional abdominal pain disorders, and GI antispasmodic use in paediatrics.
13. Urological Society of India (USI) Guidelines on Urolithiasis. Referenced for renal colic management — NSAIDs as first-line with antispasmodics as adjunctive therapy.
14. Society of Gastrointestinal Endoscopy of India (SGEI) and Indian Society of Gastroenterology (ISG) — Endoscopy procedural protocols referencing hyoscine butylbromide as standard antispasmodic adjunct during upper GI endoscopy, colonoscopy, and ERCP.
15. American Geriatrics Society 2023 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Lists ”scopolamine (hyoscine)“ as drug to avoid — clarified in this monograph as referring to hyoscine hydrobromide (crosses BBB), NOT hyoscine butylbromide (does not cross BBB). Used as additional reference for Elderly section.
16. STOPP/START Criteria version 2 (O’Mahony D et al., Age and Ageing, 2015; 44: 213–218). Referenced for antimuscarinic drug cautions in elderly patients.
17. Anticholinergic Cognitive Burden (ACB) Scale (Boustani M, Campbell N, Munger S et al., Aging Health, 2008; 4: 311–320). ACB score assignment — hyoscine butylbromide classified as ACB 1 (possible anticholinergic activity, minimal cognitive impact).
18. NPPA (National Pharmaceutical Pricing Authority) — Drug Prices Control Order (DPCO) schedule and ceiling price notifications. Hyoscine butylbromide is NOT currently price-controlled.
19. PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Product catalogue reviewed. No hyoscine butylbromide product currently listed.
20. CDSCO website (https://cdsco.gov.in) — Reviewed for banned FDC notifications, NSQ alerts, and product recall notices relevant to hyoscine butylbromide-containing formulations. No specific alerts identified for single-ingredient products.
21. PvPI (Pharmacovigilance Programme of India) — ADR reporting methodology referenced. IPC National Coordinating Centre, Indian Pharmacopoeia Commission.
22. Pallium India Training Modules — Essentials of Palliative Care. Drug formulary section referenced for antisecretory agent selection in terminal care.

---